The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions

Pharmacopsychiatry

Volumn 45, Issue 6, 2012, Pages 229-235

  Unterecker, S ^a   Hiemke, C ^b   Greiner, C ^c   Haen, E ^c   Jabs, B ^d   Deckert, J ^a   Pfuhlmann, B ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

depression treatment; pharmacokinetics; venlafaxine

Indexed keywords

DESVENLAFAXINE; PSYCHOTROPIC AGENT; VENLAFAXINE;

ADULT; AGED; ARTICLE; CIGARETTE SMOKING; COMBINATION CHEMOTHERAPY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; SMOKING;

EID: 84866431734     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1301366     Document Type: Article

References (37)

1. Harvey A T, Rudolph R L, Preskorn S H. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry: 2000; 57 503 509 (Pubitemid 30257265)
2. Holliday S M, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs: 1995; 49 280 294
3. Horst W D, Preskorn S H. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord: 1998; 51 237 254 (Pubitemid 29202173)
4. Muth E A, Moyer J A, Haskins J T et al. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res: 1991; 23 191 199
5. Gutierrez M A, Stimmel G L, Aiso J Y. Venlafaxine: a 2003 update. Clin Ther: 2003; 25 2138 2154 (Pubitemid 37076311)
6. Lecrubier Y, Bourin M, Moon C. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand: 1997; 95 485 493 (Pubitemid 27272198)
7. Linden M, Ludewig K, Munz T et al. Dosage finding and outcome of venlafaxine treatment in psychiatric outpatients and inpatients: results of a drug utilization observation study. Pharmacopsychiatry: 2003; 36 197 205 (Pubitemid 37357368)
8. Sauer H, Huppertz-Helmhold S, Dierkes W. Efficacy and safety of venlafaxine ER vs. amitriptyline ER in patients with major depression of moderate severity. Pharmacopsychiat: 2003; 36 169 175 (Pubitemid 37357363)
9. Nemeroff C B, Entsuah R, Benattia I et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry: 2008; 63 424 434
10. Shrivastava R K, Cohn C, Crowder J et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol: 1994; 14 322 329 (Pubitemid 24316929)
11. Fogelman S, Schmider J, Greenblatt D J et al. Metabolism of venlafaxine: the role of P450 isoforms. J Clin Pharmacol: 1995; 35 936 941
12. Otton S V, Ball S E, Cheung S W et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol: 1996; 41 149 156 (Pubitemid 26060742)
13. Veefkind A H, Haffmans P M, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit: 2000; 22 202 208 (Pubitemid 30196826)
14. Parks V, Patat A, Behrle J et al. Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ascending single doses of desvenlafaxine (DVS-233 SR) in healthy subjects. Clin Pharmacol Ther: 2005; 77 28
15. Perry R, Cassagnol M. Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther: 2009; 31 1374 1404
16. Choong E, Dobrinas M, Carrupt P A et al. The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution. Expert Opin Drug Metab Toxicol: 2010; 6 953 965
17. Karlsson L, Schmitt U, Josefsson M et al. Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. Eur Neuropsychopharmacol: 2010; 20 632 640
18. Hiemke C, Baumann P, Bergemann N et al. AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry: 2011; 44 195 235
19. Hiemke C. Clinical utility of drug measurements and pharmacokinetics - therapeutic drug monitoring in psychiatry. Eur J Clin Pharmacol: 2008; 64 159 166
20. Shams ME E, Arneth B, Hiemke C et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther: 2006; 31 493 502 (Pubitemid 44337299)
21. Van der Weide J, van Baalen-Benedek E H, Kootstra-Ros J E. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit: 2005; 27 478 483 (Pubitemid 41098823)
22. Reis M, Lundmark J, Björk H et al. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit: 2002; 24 545 553 (Pubitemid 34857910)
23. Reis M, Aamo T, Spigset O et al. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit: 2009; 31 42 56
24. Klamerus K J, Parker V D, Rudolph R L et al. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy: 1996; 16 915 923 (Pubitemid 26322194)
25. Alexanderson B, Evans D A, Sjoqvist F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J: 1969; 4 764 768
26. Bertilsson L, Mellström B, Sjökvist F et al. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet: 1981; 339 560 561 (Pubitemid 11130741)
27. Brosen K, Gram L F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol: 1989; 36 537 547 (Pubitemid 19175861)
28. Preskorn S, Patroneva A, Silman H et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol: 2009; 29 39 43
29. Dong S X, Ping Z Z, Xiao W Z et al. Effect of active and passive cigarette smoking on CYP1A2-mediated phenacetin disposition in Chinese subjects. Ther Drug Monit: 1998; 20 371 375
30. Berg M J. Drugs and smoking. J Gend Specif Med: 1999; 2 27 30
31. Bies R R, Bigos K L, Pollock B G. Gender differences in the pharmacokinetics and pharmacodynamics of antidepressants. J Gend Specif Med: 2003; 6 12 20 (Pubitemid 37098478)
32. Mangoni A A, Jackson S H. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol: 2004; 57 6 14 (Pubitemid 38067945)
33. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet: 2002; 41 329 342 (Pubitemid 34713088)
34. Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc: 1997; 72 835 847 (Pubitemid 27382924)
35. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol: 1996; 16 37S 50S
36. Goldberg R J. Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide. Drugs Aging: 1997; 11 119 131 (Pubitemid 27365859)
37. Grözinger M, Dragicevic A, Hiemke C et al. Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. Pharmacopsychiatry: 2003; 36 3 6 (Pubitemid 36384626)